Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company's primary product candidate is VOQUEZNA (vonoprazan), a potassium-competitive acid blocker that has completed Phase III clinical trials for multiple indications. These include erosive gastroesophageal reflux disease (GERD) and heartburn in adults, as well as non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company is also developing VOQUEZNA in combination formulations, including VOQUEZNA Triple Pak and VOQUEZNA Dual Pak for the treatment of Helicobacter pylori infection, which have completed Phase III trials.

Phathom operates as a clinical-stage biopharmaceutical company with 427 full-time employees. The company was incorporated in Delaware in 2018 and is headquartered in Florham Park, New Jersey. Phathom is publicly traded on the Nasdaq with a market capitalization of approximately $1.0 billion. The company's current focus is on advancing its pipeline candidates through regulatory approval processes and preparing for potential commercialization in the gastrointestinal therapeutics market.